« Return to News | Awards & Advancement

Mahoney becomes CEO and president of Boston Scientific

Friday, November 2, 2012 11:52 AM

Boston Scientific, a global developer, manufacturer and marketer of medical devices, has named Michael F. Mahoney its new CEO and president. Mahoney succeeds interim CEO William H. (Hank) Kucheman. Mahoney has also been appointed to the Boston Scientific board of directors. 

Mahoney has more than 24 years of healthcare experience. He joined Boston Scientific as president in October 2011. For the past year, his responsibilities have focused on the oversight of cardiac rhythm management (CRM), endoscopy (GI and pulmonary) and numerous corporate functions.

Prior to joining Boston Scientific, Mahoney held several senior positions at Johnson & Johnson, most recently worldwide chairman of the medical devices and diagnostics (MD&D) division, overseeing 50,000 employees and seven franchises. Prior to joining Johnson & Johnson, Mahoney served as president and CEO of Global Healthcare Exchange (GHX), a provider of supply chain solutions and services. He began his career at General Electric Medical Systems, where he spent 12 years successfully leading various GE Medical Systems business units in diagnostic imaging, cardiology and healthcare information technology. 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.